



bjclub

breastJournalClub



bjclub

10.11 MARZO 2017 NAPOLI



bjclub

breastJournalClub

PREMIO MIGLIORE  
STUDIO INTERNAZIONALE  
**MASSIMO CRISTOFANILLI**

PREMIO MIGLIORE  
STUDIO ITALIANO  
**LUCIA DEL MASTRO**

PREMIO SPECIALIZZANDO  
PER MIGLIORE STUDIO  
**LORENZO GERRATANA**

BOARD  
**ALBERTO BOTTINI**  
**FRANCESCO COGNETTI**  
**PIERFRANCO CONTE**  
**MICHELINO DE LAURENTIIS**  
**LUCIA DEL MASTRO**  
**SABINO DE PLACIDO**  
**LUIGI DOGLIOTTI**  
**DANIELE GENERALI**  
**LUCA GIANNI**  
**GIORGIO MUSTACCHI**  
**PAOLO PRONZATO**  
**FABIO PUGLISI**

**ECM**

Il congresso ha ottenuto 7 crediti ECM per Medico Chirurgo specializzato in Oncologia, Ginecologia e Ostetricia, Anatomia Patologica, Chirurgia Generale, Patologia Clinica, Radioterapia

**CON IL CONTRIBUTO  
INCONDIZIONATO DI**



PROGETTO ECM E  
SEGRETERIA ORGANIZZATIVA



Via Pagliari, 4  
26100 Cremona  
tel 0372 23310  
[www.ouergroup.eu](http://www.ouergroup.eu)

L'IMPORTANZA DELLA  
RICERCA IN ONCOLOGIA

**10 - 11 MARZO 2017**

**NAPOLI**

Hotel Royal Continental  
Via Partenope, 38/44

**10 Marzo 2017**

16:00 – Benvenuto e apertura lavori  
S. De Placido, M. De Laurentiis

16:15 – Presentazione e premiazione  
Massimo Cristofanilli  
S. De Placido, M. De Laurentiis

16:25 – Lettura “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial”  
M. Cristofanilli  
Discussant: F. Cognetti

16:55 – Presentazione e premiazione  
Lucia Del Mastro  
M. De Laurentiis, S. De Placido

17:05 – Lettura “Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2X2 factorial, randomised phase 3 trial”  
L. Del Mastro  
Discussant: F. Puglisi

17:35 – Premio Specializzando:  
Presentazione e Premiazione  
Lorenzo Gerratana  
V. Adamo, C. Tondini

17:45 – In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis”  
L. Gerratana  
Discussant: V. Guarneri

18:15 – TAVOLA ROTONDA  
L’accessibilità ai farmaci innovativi  
Il punto di vista dei clinici:  
S. De Placido, M. De Laurentiis  
Il punto di vista delle pazienti:  
Salute Donna – A. Mancuso  
Europa Donna – R. D’Antona  
ANDOS – F. Degrassi

19:00 – Fine lavori

**11 Marzo 2017**

09:00 – Il contributo  
dell’Associazione AIOM nella  
ricerca in oncologia  
S. Gori

09:15 - SESSIONE BEST RESEARCH  
BY YOUNG INVESTIGATORS  
A. Bottini, D. Farci

10:15 - Pearls from ESMO 2016  
M. Giuliano

10:25 - Pearls from San Antonio 2016  
D. Generali

10:35 - Studi Pre-Clinici  
P. Vigneri

SESSIONE NAB-PACLITAXEL IN EARLY  
DISEASE  
G. Mustacchi, E. Simoncini

10:45 - Evidenze cliniche di nab-paclitaxel in early disease  
P. Pronzato

11:00 - Sviluppi di nab-paclitaxel in early disease  
F. Montemurro, M. Zambetti

11:00 - NeoTRIP  
Neo-Adjuvant study with the  
PDL1-directed antibody in Triple  
Negative Locally Advanced

Breast Cancer undergoing treatment  
with nab-paclitaxel and carboplatin  
G. Bianchini

11:30 - GerparNuevo  
Addition of PD-L1 Antibody MEDI4736 to a  
Taxane-anthracycline Chemotherapy in  
Triple Negative Breast Cancer  
G. Arpino

11:40 - Wave  
Weekly nab-paclitaxel Versus Epirubicin in  
women with early breast cancer elderly or  
unfit for a 3-weekly polychemotherapy  
regimen: a Phase II Randomized Trial  
evaluating Activity and Quality of Life  
M. De Laurentiis  
Discussant: F. Puglisi

11:50 – Coffee Break

SESSIONE NAB-PACLITAXEL IN  
ADVANCED DISEASE  
PF. Conte

12:00 - TNACITY  
Phase 2/3, multi-center, open-label,  
randomized study of weekly  
Nab-paclitaxel in combination  
with gemcitabine or

carboplatin, vs gemcitabine /  
carboplatin, as first-line treatment in  
TNMBC Abraxane 125mg/ m2,  
Gemcitabine 1000mg/m2, Carboplatin  
AUC2 days 1,8 cycles 21 days  
M.V. Dieci

12:10 - SNAP  
A randomized phase II study evaluating  
three different schedules of nab-paclitaxel as  
maintenance therapy  
A. Gennari

12:20 - GIM 13 – AMBRA  
Longitudinal, observational study on the  
choices of chemotherapy for HER2-negative  
metastatic breast cancer in the clinical  
practice  
M. Cazzaniga

12:30 - EFFECT  
Evaluation of the efficacy and impact on  
patient functioning of two doses of  
nab-paclitaxel in elderly (>65 yrs) breast  
cancer patients  
L. Biganzoli

12:40 - ABRAMYO  
Phase II, multicenter open label  
study in patients with previously

untreated metastatic breast cancer  
Nab-paclitaxel 100\_125 mg/ m2 and  
with LDox 20\_25 mg/ m2 will be  
administered on days 1, 8, 15 of a 28-day  
cycle until disease progression  
A. Fabi

12:50 - IMpassion130  
A study of Atezolizumab in combination with  
nab-paclitaxel compared with placebo with  
nab-paclitaxel for participants with  
previously untreated metastatic triple  
negative breast cancer  
M. De Laurentiis  
Discussant: C. Zamagni

13:00 – Conclusioni e take home  
messages  
S. De Placido, M. De Laurentiis

13:15 – Compilazione questionario di  
valutazione ECM

13:30 – Fine lavori